Who is sponsoring NCT05827289?

NCT05827289 is sponsored by The Netherlands Cancer Institute.

What drugs are being tested in NCT05827289?

Interventions in NCT05827289: Cancer Patients Better Life Experience (CAPABLE).

Is NCT05827289 still recruiting?

NCT05827289 is currently status unknown. Last updated 6 July 2023.

Last reviewed 2023-07-06 · How we verify

NCT05827289: CAPABLE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

'Cancer Patients Better Life Experience'

Status unknown NA Last updated 6 July 2023

What this trial tests

NA trial testing Cancer Patients Better Life Experience (CAPABLE) in Melanoma in 36 participants. Status unknown.

Timeline

15 April 2023

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	The Netherlands Cancer Institute
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	36
Start date	15 April 2023
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Netherlands

Drugs / interventions tested

Cancer Patients Better Life Experience (CAPABLE)

Conditions studied

Melanoma — all drugs for Melanoma →

Sponsor

The Netherlands Cancer Institute

Who can join

18 and older, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare health-related quality of life, specifically fatigue, in melanoma patients treated with immunotherapy who use or do not use a patient-centered mobile coaching and monitoring system (CAPABLE). It is expected that by using the CAPABLE eHealth tool, patients' fatigue worsens less significantly (10 points) in the first 3 months follow-up than observed in usual care.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial.
Fraterman I, Wollersheim BM, Tibollo V, Glaser SLC, et al · · 2023 · cited 7× · PMID 37819691 · DOI 10.2196/49252
Impact of Physical Exercise on Melanoma Hallmarks: Current Status of Preclinical and Clinical Research.
Ceci C, García-Chico C, Atzori MG, Lacal PM, et al · · 2024 · cited 4× · PMID 38164270 · DOI 10.7150/jca.88559
Obtaining Patient-Reported Outcome Data via a Home Patient Monitoring App: Development, Implementation, and Validation of Novel Interface Terminology.
Sacchi L, Lanzola G, Quaglini S, Veggiotti N, et al · · 2025 · PMID 41380016 · DOI 10.2196/65504
Exploring the Impact of the Multimodal CAPABLE eHealth Intervention on Health-Related Quality of Life in Patients With Melanoma Undergoing Immune-Checkpoint Inhibition: Prospective Pilot Study.
Fraterman I, Sacchi L, Mallo H, Tibollo V, et al · · 2025 · PMID 39883020 · DOI 10.2196/58938

Verify or expand the search:

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other The Netherlands Cancer Institute trials

Trials by the same sponsor.

NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05827289 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
Last refreshed: 6 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05827289.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing